- Our World
- Our Business
- Life at Lupin
- Global Sites
Lupin’s Intellectual Property Management Group (IPMG) is responsible for building Lupin’s global generic product pipeline as well as creating, managing and protecting its high-value patent estate. The Company’s IPMG has become a benchmark in the industry for its litigation track record and carrying out patent challenges successfully.
In FY 2016, Lupin successfully launched the generic versions of Glumetza®, Intermezzo®, Loestrin® 24 Fe, Phoslo Gelcaps®, Generess®, Mircette®, Lofibra®, Ortho Tri-Cyclen Lo® to name a few.
During the year, the Company also settled 5 pending litigations as well as got favorable decisions or oppositions on Celebrex®, Intermezzo® and Teneligliptin.
In FY 2016, the Company filed 325 patent applications including 136 new inventions taking the cumulative total to 2,525 patents filed till date in India and other countries. This included 57 Formulation patents, 75 API/Process patents, 33 Biotech and 160 NDDD patents. Lupin received approvals for 22 Formulation patents, 11 API patents and more importantly 41 NCE patents in the year.